NellOne Therapeutics

company

About

NellOne Therapeutics develops Nell1 protein therapeutics for restoring tissue mass and function in patients recovering from heart attacks.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$242.34K
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2007
Number Of Employee
1 - 10
Operating Status
Active

NellOne Therapeutics is a regenerative medicine company that has been spun out of the U.S. Department of Energy's Oak Ridge National Laboratory in Oak Ridge, Tenn.

Senior Staff Scientist Dr. Cymbeline Culiat in the Lab's Biosciences Division / Systems Genetics Group had identified the activity of the Nell1 gene's pathway in the formation of key mammalian tissues and organs, and Battelle Ventures founded NellOne to translate her basic science discovery into clinical applications.

The company is dedicated to developing and commercializing Nell1 protein therapeutics for restoring tissue mass and function in patients recovering from heart attacks.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$242.34K
NellOne Therapeutics has raised a total of $242.34K in funding over 2 rounds. Their latest funding was raised on Mar 31, 2021 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 31, 2021 Grant $242.34K 1 National Science Foundation Detail

Investors

Number of Lead Investors
Number of Investors
1
1
NellOne Therapeutics is funded by 1 investors. National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant